Stage and tissue-specific prognostic impact of miR-182 in NSCLC

dc.contributor.author	Stenvold, Helge
dc.contributor.author	Dønnem, Tom
dc.contributor.author	Andersen, Sigve
dc.contributor.author	Al-Saad, Samer
dc.contributor.author	Busund, Lill-Tove
dc.contributor.author	Bremnes, Roy M.
dc.date.accessioned	2015-03-12T14:19:54Z
dc.date.available	2015-03-12T14:19:54Z
dc.date.issued	2014
dc.identifier.citation	BMC Cancer 2014, 14:138	en_US
dc.identifier.cristinID	FRIDAID 1162965
dc.identifier.doi	10.1186/1471-2407-14-138
dc.identifier.issn	1471-2407
dc.identifier.uri	https://hdl.handle.net/10037/7459
dc.identifier.urn	URN:NBN:no-uit_munin_7036
dc.language.iso	eng	en_US
dc.publisher	BioMed Central	en_US
dc.rights.accessRights	openAccess
dc.subject	VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762	en_US
dc.subject	VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762	en_US
dc.title	Stage and tissue-specific prognostic impact of miR-182 in NSCLC	en_US
dc.type	Journal article	en_US
dc.type	Tidsskriftartikkel	en_US
dc.type	Peer reviewed	en_US